In Q3FY16, total revenues of Alembic Pharmaceuticals increased by 80.1% YoY to Rs 9.2 bn (our estimates Rs 9.4 bn) compared to Rs 5.1 bn in Q3FY15, due to higher export formulations sales on account of revenues generated from Abilify opportunity.